Reliance Global Group (EZRA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Sep, 2026Executive summary
Organization simplified and balance sheet strengthened through divestitures and operational streamlining, positioning for long-term growth.
Leadership team enhanced with new COO, CTO, and EVP appointments to drive operational and technological advancement.
Launched and deployed proprietary AI agent for secure browser automation, advancing AI strategy and operational transformation.
Continued organic growth in retained insurance businesses following divestiture of non-core operations.
Strategic focus shifted to supporting existing technology and life sciences investments, with reduced new investment activity.
Financial highlights
Q2 2026 commission income was $2.1 million, down from $3.1 million year-over-year due to divestitures and portfolio realignment.
Operating expenses for Q2 2026 were $3.9 million, down 28% year-over-year due to efficiency initiatives.
Net loss improved by 26% year-over-year to $2.0 million from $2.7 million in the prior-year quarter.
Adjusted EBITDA loss was $1.1 million, compared to a $0.4 million loss in the prior year quarter.
As of June 30, 2026: cash and restricted cash totaled $1.8 million, working capital was $1.2 million, and stockholders' equity was $6.6 million.
Outlook and guidance
Continued enhancement and deployment of proprietary AI platform across the organization to optimize workflows and reduce administrative burdens.
AI platform expected to begin generating revenue within six to nine months, with expense reductions already realized.
Management believes current liquidity and access to capital are sufficient for at least the next 12 months.
Ongoing evaluation of commercialization opportunities for AI technology and disciplined approach to capital allocation.
Strategic focus remains on insurance operations, with selective support for technology and life sciences investments.
Latest events from Reliance Global Group
- Equity line registration enables up to $50M in funding but brings major dilution and compliance risks.EZRA
Registration filing - Net loss improved, cash and equity grew, and insurance saw 11% organic growth.EZRA
Q1 2026 - All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing - Annual meeting seeks approval for director elections, equity plan expansion, and major share issuance.EZRA
Proxy filing - Shareholders will vote on director elections, equity plan expansion, and a $50M share issuance.EZRA
Proxy Filing - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 2025 - Raising $5.3M for growth, tech, and digital assets amid dilution and Nasdaq compliance risks.EZRA
Registration Filing - Q2 net loss improved 62%, Spetner deal to double revenue and boost profitability.EZRA
Q2 2024